Abstract: Objective To evaluate the efficacy and toxicity of Paclitaxel(PTX) combined with Adriamycin(ADM) or cisplatin(DDP) in treating advanced breast cancer.Methods Thirty-five patients with advanced breast cancer were treated with PTX 135mg/m2 on d1 plus ADM 40mg/m2 on d1 or DDP 30 mg/m2 on d1~3.One cycle included 21～28 days treatment and each patient was given 2 cycles at least.Results 35 patients were evaluated for clinical response.The response rate in TA group was 52.6%(10/19),in TP group was 43.8%(7/16).The median remission period of TA and TP group was 8.6 and 7.8 months respectively,while the median survival period of TA and TP group was 14.5 and 13.8 months respectively.The differences of efficacy and median response duration between the two groups were not significantly(P>0.05).Main side effects included leukopenia,gastroenteric reaction and alopecia.Conclusions Paclitaxel-combined chemotherapy is effective for treating advanced breast cancer.There is no significant difference between the two programs.Both programs can be used as the first-line treatment for advanced breast cancer.

Key words: Paclitaxel, Adriamycin, Cisplatin, Breast cancer